GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006979111 | Esophagus | ESCC | response to oxidative stress | 303/8552 | 446/18723 | 7.15e-22 | 1.30e-19 | 303 |
GO:0062197111 | Esophagus | ESCC | cellular response to chemical stress | 234/8552 | 337/18723 | 5.37e-19 | 5.97e-17 | 234 |
GO:0034599111 | Esophagus | ESCC | cellular response to oxidative stress | 197/8552 | 288/18723 | 3.76e-15 | 2.15e-13 | 197 |
GO:0000302111 | Esophagus | ESCC | response to reactive oxygen species | 150/8552 | 222/18723 | 3.06e-11 | 1.02e-09 | 150 |
GO:003461420 | Esophagus | ESCC | cellular response to reactive oxygen species | 103/8552 | 155/18723 | 1.34e-07 | 2.17e-06 | 103 |
GO:00069797 | Liver | NAFLD | response to oxidative stress | 78/1882 | 446/18723 | 7.85e-07 | 4.29e-05 | 78 |
GO:00621977 | Liver | NAFLD | cellular response to chemical stress | 54/1882 | 337/18723 | 3.83e-04 | 5.73e-03 | 54 |
GO:00003027 | Liver | NAFLD | response to reactive oxygen species | 38/1882 | 222/18723 | 7.63e-04 | 9.63e-03 | 38 |
GO:00345997 | Liver | NAFLD | cellular response to oxidative stress | 46/1882 | 288/18723 | 1.07e-03 | 1.25e-02 | 46 |
GO:000697922 | Liver | HCC | response to oxidative stress | 281/7958 | 446/18723 | 9.75e-19 | 1.24e-16 | 281 |
GO:006219722 | Liver | HCC | cellular response to chemical stress | 216/7958 | 337/18723 | 6.86e-16 | 5.44e-14 | 216 |
GO:003459922 | Liver | HCC | cellular response to oxidative stress | 183/7958 | 288/18723 | 3.65e-13 | 1.93e-11 | 183 |
GO:000030222 | Liver | HCC | response to reactive oxygen species | 144/7958 | 222/18723 | 1.24e-11 | 5.09e-10 | 144 |
GO:003461412 | Liver | HCC | cellular response to reactive oxygen species | 102/7958 | 155/18723 | 3.70e-09 | 9.89e-08 | 102 |
GO:0006979113 | Thyroid | PTC | response to oxidative stress | 234/5968 | 446/18723 | 6.97e-20 | 9.77e-18 | 234 |
GO:0062197113 | Thyroid | PTC | cellular response to chemical stress | 180/5968 | 337/18723 | 1.36e-16 | 1.16e-14 | 180 |
GO:0034599113 | Thyroid | PTC | cellular response to oxidative stress | 151/5968 | 288/18723 | 2.82e-13 | 1.43e-11 | 151 |
GO:0000302113 | Thyroid | PTC | response to reactive oxygen species | 121/5968 | 222/18723 | 2.10e-12 | 9.26e-11 | 121 |
GO:0034614112 | Thyroid | PTC | cellular response to reactive oxygen species | 82/5968 | 155/18723 | 4.32e-08 | 9.27e-07 | 82 |
GO:000697934 | Thyroid | ATC | response to oxidative stress | 246/6293 | 446/18723 | 2.98e-21 | 6.09e-19 | 246 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ERCC6L2 | SNV | Missense_Mutation | rs866677625 | c.625N>T | p.Ser209Leu | p.S209L | | protein_coding | tolerated(0.74) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ERCC6L2 | SNV | Missense_Mutation | | c.2015C>T | p.Ala672Val | p.A672V | Q5T890 | protein_coding | deleterious(0.03) | benign(0.011) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ERCC6L2 | SNV | Missense_Mutation | | c.651C>T | p.His218Tyr | p.H218Y | | protein_coding | tolerated(0.31) | benign(0.007) | TCGA-AO-A03P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | PD |
ERCC6L2 | SNV | Missense_Mutation | rs200972525 | c.1859N>G | p.Asn620Ser | p.N620S | Q5T890 | protein_coding | tolerated(0.09) | benign(0.125) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
ERCC6L2 | insertion | Frame_Shift_Ins | novel | c.793_794insGTGTTTTT | p.Leu265ArgfsTer34 | p.L265Rfs*34 | Q5T890 | protein_coding | | | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ERCC6L2 | insertion | In_Frame_Ins | novel | c.795_796insTTT | p.Leu265_Arg266insPhe | p.L265_R266insF | Q5T890 | protein_coding | | | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ERCC6L2 | insertion | In_Frame_Ins | novel | c.1293_1294insAAAAAAATTCTA | p.Thr431_Cys432insLysLysIleLeu | p.T431_C432insKKIL | Q5T890 | protein_coding | | | TCGA-B6-A0IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
ERCC6L2 | insertion | Nonsense_Mutation | novel | c.1295_1296insAGGTTTATTTGAAAGTGAAATTATACTT | p.Cys432Ter | p.C432* | Q5T890 | protein_coding | | | TCGA-B6-A0IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
ERCC6L2 | deletion | Frame_Shift_Del | novel | c.1345delN | p.Gly449ValfsTer4 | p.G449Vfs*4 | Q5T890 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ERCC6L2 | SNV | Missense_Mutation | | c.418N>A | p.Glu140Lys | p.E140K | Q5T890 | protein_coding | deleterious(0.03) | probably_damaging(0.968) | TCGA-IR-A3LI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |